Cost-effectiveness associated with amyotrophic lateral sclerosis: some questions and answers pending

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):315-316. doi: 10.1080/21678421.2017.1408126. Epub 2017 Nov 30.

Authors

Giuseppe Fiorentino¹, Antonio M Esquinas²

Affiliations

¹ a Malattie e Riabilitazione Respiratoria , AO Ospedali dei Colli Napoli, PO Monaldi , Naples , Italy and.
² b Intensive Care Unit , Hospital Morales Meseguer , Murcia , Spain.

PMID: 29191046
DOI: 10.1080/21678421.2017.1408126

No abstract available

Publication types

Letter

MeSH terms

Amyotrophic Lateral Sclerosis / economics*
Amyotrophic Lateral Sclerosis / therapy*
Cost-Benefit Analysis
Humans
Neuroprotective Agents / economics*
Neuroprotective Agents / therapeutic use
Riluzole / economics*
Riluzole / therapeutic use

Substances

Neuroprotective Agents
Riluzole